Science Group plc (SAG)
London Exchange · UK · prices in GBX · close of 19 Oct 2026
Key indicators
| Last close | GBX 570.00 |
|---|---|
| 52-week range | 511.11 – 601.54 |
| Return, 1 month / 3 months | −0.9% / −2.6% |
| Return, 1 year / 3 years | +5.0% / +47.6% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 38 |
| Volatility (1 year) | 16.1% |
| Worst drawdown (1 year) | -9.3% |
| Average daily value traded | 27.11M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Science Group plc is a professional services company based in the United Kingdom that provides scientific, technical and regulatory consulting to clients in sectors such as medical devices, food and drink, and consumer products. Its specialists help customers with product development, testing, compliance and advisory work, and the group also offers engineering and technology consulting through its operating businesses. Clients include established manufacturers and other organisations seeking independent scientific and technical expertise.
Science Group plc trades under the code SAG on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Science Group plc (SAG) trades on the London Exchange in UK. It last closed at GBX 570.00 on 19 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 845 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.0% and over the last three months it fell 2.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 63 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.3% | ||
| From 52-week high | -5.2% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -2.6% | ||
| 6-month return | 0.9% | ||
| 12-month return, skipping the last month | 5.9% | ||
| Stability (higher is calmer) | 94 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 16.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -9.3% | ||
| Liquidity | 81 · Strong | Trades actively. | |
| Average daily value traded | 27.11M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −0.9% |
| 3 months | −2.6% |
| 6 months | +0.9% |
| 1 year | +5.0% |
| 3 years | +47.6% |
| 5 years | +32.5% |
Signals
| 50-day / 200-day average | 575.24 / 562.91 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 May 2026 | GBP 0.1000 |
| 22 May 2025 | GBP 0.0800 |
| 20 Jun 2024 | GBP 0.0800 |
| 18 May 2023 | GBP 0.0500 |
| 19 May 2022 | GBP 0.0500 |
| 20 May 2021 | GBP 0.0400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.